The dual-action GLP-1 + GIP drug — complete patient guide.
Mounjaro (tirzepatide) is a once-weekly injectable medication made by Eli Lilly, FDA-approved in May 2022 for type 2 diabetes. It belongs to a new class of drugs called dual GIP/GLP-1 receptor agonists — the first drug to simultaneously activate both the GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) hormone receptors.
This dual mechanism makes Mounjaro more powerful than single GLP-1 drugs like Ozempic and Wegovy for weight loss. Clinical trials show approximately 20% average body weight reduction — the highest of any medication ever studied for obesity. Its weight-loss-approved twin, Zepbound, contains the same active ingredient (tirzepatide) with an obesity-specific FDA approval.
The combination is why SURMOUNT-5 showed tirzepatide produces 47% more weight loss than semaglutide in direct comparison.
Mounjaro titrates over 20 weeks to reach the maximum 15mg dose. Unlike semaglutide, the dose numbers are larger — but don't be intimidated, the doses are in different units (mg, not mcg).
The SURPASS clinical trial program for Mounjaro showed impressive results across all doses:
Side effects are similar to semaglutide-based drugs but may be slightly more pronounced due to the dual mechanism and higher dose range. GI effects dominate, especially during titration.
| Scenario | Monthly Cost |
|---|---|
| List price | ~$1,023 |
| Commercial insurance (diabetes) | ~$25–$50 |
| Eli Lilly savings card | ~$25/mo (if eligible) |
| Medicare Part D | ~$30–$80 |
| No insurance | ~$1,023 |
| Factor | Mounjaro | Ozempic |
|---|---|---|
| Mechanism | GLP-1 + GIP (dual) | GLP-1 only |
| Avg Weight Loss | ~20% | ~15% |
| Heart Data | ⏳ Pending | ✅ Proven |
| Nausea | Moderate-High | Moderate |
| List Price | ~$1,023/mo | ~$935/mo |
| Winner | Weight loss | Heart benefit, cost |
Yes — Mounjaro and Zepbound are the same drug (tirzepatide) made by Eli Lilly. The only difference is the FDA approval:
For weight loss, yes — significantly. SURMOUNT-5 showed 47% more weight loss with tirzepatide vs semaglutide. For proven cardiovascular benefit, Ozempic/Wegovy have more data. Mounjaro is newer and cardiovascular outcome trials are still ongoing.
Mounjaro is only FDA-approved for type 2 diabetes. For obesity without diabetes, Zepbound is the correct drug. Doctors sometimes prescribe Mounjaro off-label for weight loss, but insurance likely won't cover it for that purpose.
Appetite reduction typically starts within 1–3 weeks. Visible weight loss is usually seen by weeks 4–8. Maximum results occur at the 10–15mg dose range, which patients reach around weeks 17–20+.
Mounjaro's long-term safety profile is still being established — it was approved in 2022. So far, the safety data from 2+ year clinical trial follow-ups is reassuring. The main long-term concerns are thyroid C-cell tumors (seen in animals, not confirmed in humans), gallstones, and muscle loss with rapid weight loss.